220 related articles for article (PubMed ID: 22699400)
1. The gastrointestinal pharmacology of cannabinoids: focus on motility.
Abalo R; Vera G; López-Pérez AE; Martínez-Villaluenga M; Martín-Fontelles MI
Pharmacology; 2012; 90(1-2):1-10. PubMed ID: 22699400
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids and the gut: new developments and emerging concepts.
Izzo AA; Sharkey KA
Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
[TBL] [Abstract][Full Text] [Related]
3. The gastrointestinal pharmacology of cannabinoids: an update.
Coutts AA; Izzo AA
Curr Opin Pharmacol; 2004 Dec; 4(6):572-9. PubMed ID: 15525546
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids and gastrointestinal motility: animal and human studies.
Aviello G; Romano B; Izzo AA
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():81-93. PubMed ID: 18924447
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid pharmacology and therapy in gut disorders.
Uranga JA; Vera G; Abalo R
Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849
[TBL] [Abstract][Full Text] [Related]
6. Gut feelings about the endocannabinoid system.
Di Marzo V; Piscitelli F
Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids and the digestive tract.
Izzo AA; Coutts AA
Handb Exp Pharmacol; 2005; (168):573-98. PubMed ID: 16596788
[TBL] [Abstract][Full Text] [Related]
8. Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease.
Gotfried J; Naftali T; Schey R
Gastroenterology; 2020 Jul; 159(1):62-80. PubMed ID: 32333910
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids as gastrointestinal anti-inflammatory drugs.
Fabisiak A; Fichna J
Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 28239924
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids and the gastrointestinal tract.
Massa F; Monory K
J Endocrinol Invest; 2006; 29(3 Suppl):47-57. PubMed ID: 16751708
[TBL] [Abstract][Full Text] [Related]
11. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
Hasenoehrl C; Taschler U; Storr M; Schicho R
Neurogastroenterol Motil; 2016 Dec; 28(12):1765-1780. PubMed ID: 27561826
[TBL] [Abstract][Full Text] [Related]
12. The cannabinoid CB(2) receptor: a good friend in the gut.
Izzo AA
Neurogastroenterol Motil; 2007 Sep; 19(9):704-8. PubMed ID: 17727390
[TBL] [Abstract][Full Text] [Related]
13. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
Shook JE; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):444-9. PubMed ID: 2542532
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects.
Izzo AA; Camilleri M
Gut; 2008 Aug; 57(8):1140-55. PubMed ID: 18397936
[TBL] [Abstract][Full Text] [Related]
15. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions.
Fornai M; Antonioli L; Colucci R; Bernardini N; Ghisu N; Tuccori M; De Giorgio R; Del Tacca M; Blandizzi C
Pharmacol Ther; 2010 Jan; 125(1):62-78. PubMed ID: 19808045
[TBL] [Abstract][Full Text] [Related]
17. The participation of the sympathetic innervation of the gastrointestinal tract in disease states.
Lomax AE; Sharkey KA; Furness JB
Neurogastroenterol Motil; 2010 Jan; 22(1):7-18. PubMed ID: 19686308
[TBL] [Abstract][Full Text] [Related]
18. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
Katzka DA; Loftus EV; Camilleri M
Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
[TBL] [Abstract][Full Text] [Related]
19. Capsaicin research as a new tool to approach of the human gastrointestinal physiology, pathology and pharmacology.
Mózsik G; Szolcsányi J; Dömötör A
Inflammopharmacology; 2007 Dec; 15(6):232-45. PubMed ID: 18236014
[TBL] [Abstract][Full Text] [Related]
20. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
